Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study to Evaluate the Safety, Tolerability, PK and Pharmacodynamics of 3 Dosages of Estetrol, the Lowest Dose of 2 mg Estetrol Compared With 2 mg of E2, After Daily Oral Administration for 28 Days in Healthy Postmenopausal Women

NCT00163033 is registered in ClinicalTrials.gov with Pantarhei Bioscience as lead sponsor.

NCT NCT00163033
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00163033 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study to Evaluate the Safety, Tolerability, PK and Pharmacodynamics of 3 Dosages of Estetrol, the Lowest Dose of 2 mg Estetrol Compared With 2 mg of E2, After Daily Oral Administration for 28 Days in Healthy Postmenopausal Women
Lead sponsor
Pantarhei Bioscience
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2005
Completion date
September 30, 2007
Enrollment
49 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy